Cargando…
Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma
OBJECTIVE: There is still no definitely therapeutic evidence of a beneficial effect of chemotherapy with radiotherapy for older patients with esophageal squamous cell carcinoma (ESCC). We aim to determine the influence of chemoradiotherapy (CRT) and radiotherapy (RT) alone in patients aged 65 years...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557531/ https://www.ncbi.nlm.nih.gov/pubmed/34717670 http://dx.doi.org/10.1186/s13014-021-01931-1 |
_version_ | 1784592390703546368 |
---|---|
author | Wu, Haishan Yu, Yilin Zheng, Qunhao Liu, Tianxiu Wu, Yahua Wang, Zhiping Zheng, Hongying Liu, Lingyun Li, Jiancheng |
author_facet | Wu, Haishan Yu, Yilin Zheng, Qunhao Liu, Tianxiu Wu, Yahua Wang, Zhiping Zheng, Hongying Liu, Lingyun Li, Jiancheng |
author_sort | Wu, Haishan |
collection | PubMed |
description | OBJECTIVE: There is still no definitely therapeutic evidence of a beneficial effect of chemotherapy with radiotherapy for older patients with esophageal squamous cell carcinoma (ESCC). We aim to determine the influence of chemoradiotherapy (CRT) and radiotherapy (RT) alone in patients aged 65 years or older with locally advanced ESCC. METHODS: We retrospectively analyzed 581 ESCC patients who underwent CRT and RT alone. Univariate and multivariate Cox regression analysis was used to analyze the impact of clinical factors on long‐term overall survival (OS) and progression-free survival (PFS). Finally, we compared the toxicity rates of these patients. RESULTS: The median OS and PFS of the overall population were 23.2 months (2.0–162.6 months) and 18.6 months (1.1–159.6 months). Multivariate Cox regression analysis showed that chemotherapy (p < 0.05), tumor thickness (p < 0.01), and N stage (p < 0.05) were independent prognostic factors associated with both OS and PFS. In the chemotherapy subgroup, patients who received 2–8 cycles of chemotherapy had better OS than those who received 1 cycle (p = 0.015). The results also revealed that the CRT group has better OS and PFS than RT alone group for patients aged 65–74 years (both p < 0.01). However, for patients aged 75 years or older, there was no statistically significant difference between CRT and RT alone (both p > 0.05). Besides, higher staged ESCC has the inferior OS and PFS than lower staged ESCC for patients received RT alone and aged 65–74 years (both p < 0.05). Finally, there were significantly more severe hematologic toxicities in the CRT group than in those treated with RT alone in this study (p < 0.001). CONCLUSIONS: The present study suggested that CRT for locally advanced ESCC in patients aged 65 years or older had a significant benefit over RT alone in terms of OS and PFS. However, for patients aged 75 years or older, there was no statistically significant difference between CRT and RT alone. CRT should be performed with special attention in patients aged 75 years or older. |
format | Online Article Text |
id | pubmed-8557531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85575312021-11-01 Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma Wu, Haishan Yu, Yilin Zheng, Qunhao Liu, Tianxiu Wu, Yahua Wang, Zhiping Zheng, Hongying Liu, Lingyun Li, Jiancheng Radiat Oncol Research OBJECTIVE: There is still no definitely therapeutic evidence of a beneficial effect of chemotherapy with radiotherapy for older patients with esophageal squamous cell carcinoma (ESCC). We aim to determine the influence of chemoradiotherapy (CRT) and radiotherapy (RT) alone in patients aged 65 years or older with locally advanced ESCC. METHODS: We retrospectively analyzed 581 ESCC patients who underwent CRT and RT alone. Univariate and multivariate Cox regression analysis was used to analyze the impact of clinical factors on long‐term overall survival (OS) and progression-free survival (PFS). Finally, we compared the toxicity rates of these patients. RESULTS: The median OS and PFS of the overall population were 23.2 months (2.0–162.6 months) and 18.6 months (1.1–159.6 months). Multivariate Cox regression analysis showed that chemotherapy (p < 0.05), tumor thickness (p < 0.01), and N stage (p < 0.05) were independent prognostic factors associated with both OS and PFS. In the chemotherapy subgroup, patients who received 2–8 cycles of chemotherapy had better OS than those who received 1 cycle (p = 0.015). The results also revealed that the CRT group has better OS and PFS than RT alone group for patients aged 65–74 years (both p < 0.01). However, for patients aged 75 years or older, there was no statistically significant difference between CRT and RT alone (both p > 0.05). Besides, higher staged ESCC has the inferior OS and PFS than lower staged ESCC for patients received RT alone and aged 65–74 years (both p < 0.05). Finally, there were significantly more severe hematologic toxicities in the CRT group than in those treated with RT alone in this study (p < 0.001). CONCLUSIONS: The present study suggested that CRT for locally advanced ESCC in patients aged 65 years or older had a significant benefit over RT alone in terms of OS and PFS. However, for patients aged 75 years or older, there was no statistically significant difference between CRT and RT alone. CRT should be performed with special attention in patients aged 75 years or older. BioMed Central 2021-10-30 /pmc/articles/PMC8557531/ /pubmed/34717670 http://dx.doi.org/10.1186/s13014-021-01931-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Wu, Haishan Yu, Yilin Zheng, Qunhao Liu, Tianxiu Wu, Yahua Wang, Zhiping Zheng, Hongying Liu, Lingyun Li, Jiancheng Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma |
title | Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma |
title_full | Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma |
title_fullStr | Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma |
title_full_unstemmed | Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma |
title_short | Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma |
title_sort | benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557531/ https://www.ncbi.nlm.nih.gov/pubmed/34717670 http://dx.doi.org/10.1186/s13014-021-01931-1 |
work_keys_str_mv | AT wuhaishan benefitofchemotherapybasedonplatinumwithdefinitiveradiotherapyinolderpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT yuyilin benefitofchemotherapybasedonplatinumwithdefinitiveradiotherapyinolderpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT zhengqunhao benefitofchemotherapybasedonplatinumwithdefinitiveradiotherapyinolderpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT liutianxiu benefitofchemotherapybasedonplatinumwithdefinitiveradiotherapyinolderpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT wuyahua benefitofchemotherapybasedonplatinumwithdefinitiveradiotherapyinolderpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT wangzhiping benefitofchemotherapybasedonplatinumwithdefinitiveradiotherapyinolderpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT zhenghongying benefitofchemotherapybasedonplatinumwithdefinitiveradiotherapyinolderpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT liulingyun benefitofchemotherapybasedonplatinumwithdefinitiveradiotherapyinolderpatientswithlocallyadvancedesophagealsquamouscellcarcinoma AT lijiancheng benefitofchemotherapybasedonplatinumwithdefinitiveradiotherapyinolderpatientswithlocallyadvancedesophagealsquamouscellcarcinoma |